116 Barrie Street, Suite 2424
Bioscience Complex
Queen’s University
Kingston, Ontario
Canada K7L 3N6
Phone: 613-531-9995

Robert L. Foldes, president and CEO
Privately Held


Cytochroma Inc. is an applied genomics and drug discovery company focusing on cytochrome P450 genes, the identification of the function of the proteins encoded by those genes, and the discovery of potent and specific drugs regulating cytochrome P450 enzymes.

The enzymes play key roles in regulating major signaling pathways and represent targets for the treatment of many diseases. Cytochroma uses bioinformatics and gene sequence information in public databases to identify new members of the cytochrome P450 family.

The company’s drug discovery program is developing therapeutics based on modulators of retinoic acid and calcitriol metabolism for skin diseases, such as psoriasis, acne and photoaging, and for cancer, initially focusing on lung, breast and prostate cancer and leukemia.


Continuation and expansion of cytochrome P450 enzyme research, development and license agreement to develop inhibitors of retinoic acid metabolism: Allergan Inc.

Collaboration to search for novel genes to enhance Cytochroma’s library of validated molecular targets for drug discovery: Molecular Mining Corp.

Exclusive worldwide rights to commercialize intellectual property portfolio relating to noncalcemic, antiproliferative and transcriptionally active vitamin D analogues (includes collaboration focusing on the discovery and design of vitamin D-related compounds that inhibit the activity of CYP24): Johns Hopkins University.